UPSTREAM BIO, INC.
NASDAQ: UPB (Upstream Bio, Inc.)
Kemas kini terakhir: semalam, 8:38PM27.75
0.01 (0.04%)
| Penutupan Terdahulu | 27.74 |
| Buka | 27.82 |
| Jumlah Dagangan | 393,225 |
| Purata Dagangan (3B) | 441,393 |
| Modal Pasaran | 1,499,570,944 |
| Harga / Jualan (P/S) | 482.50 |
| Harga / Buku (P/B) | 3.57 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Nov 2025 |
| Margin Operasi (TTM) | -5,656.01% |
| EPS Cair (TTM) | -1.67 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -11.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.38% |
| Nisbah Semasa (MRQ) | 47.43 |
| Aliran Tunai Operasi (OCF TTM) | -82.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -70.18 M |
| Pulangan Atas Aset (ROA TTM) | -16.91% |
| Pulangan Atas Ekuiti (ROE TTM) | -28.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Upstream Bio, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | 0.50 |
|
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 14.84% |
| % Dimiliki oleh Institusi | 89.32% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Decheng Capital Llc | 30 Sep 2025 | 3,285,293 |
| Enavate Sciences Gp, Llc | 30 Sep 2025 | 2,459,703 |
| Tcg Crossover Management, Llc | 30 Sep 2025 | 2,117,103 |
| Altshuler Shaham Ltd | 30 Sep 2025 | 1,416,822 |
| Omega Fund Management, Llc | 30 Sep 2025 | 1,356,293 |
| Samsara Biocapital, Llc | 30 Sep 2025 | 962,154 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 47.00 (Truist Securities, 69.37%) | Beli |
| Median | 43.00 (54.96%) | |
| Rendah | 40.00 (Evercore ISI Group, 44.14%) | Beli |
| Purata | 43.33 (56.14%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 23.52 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| LifeSci Capital | 02 Dec 2025 | 43.00 (54.95%) | Beli | 25.01 |
| Evercore ISI Group | 18 Nov 2025 | 40.00 (44.14%) | Beli | 25.56 |
| Truist Securities | 14 Oct 2025 | 47.00 (69.37%) | Beli | 19.98 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Nov 2025 | Pengumuman | Upstream Bio to Participate in Upcoming December Investor Conferences |
| 05 Nov 2025 | Pengumuman | Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress |
| 31 Oct 2025 | Pengumuman | Upstream Bio to Participate in Upcoming November Investor Conferences |
| 30 Sep 2025 | Pengumuman | Upstream Bio Presents Data Showing Structural and Mechanistic Drivers of Verekitug’s Potent Pharmacodynamic Activity and Differentiated Clinical Profile at European Respiratory Society Congress |
| 09 Sep 2025 | Pengumuman | Upstream Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |